Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies
- PMID: 27537995
Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies
Abstract
Background: Calcipotriene 0.005% (Cal)/betamethasone dipropionate 0.064% (BD) aerosol foam was developed as a new treatment option for patients with psoriasis. This pooled analysis evaluated the efficacy of this formulation for 4 weeks of treatment.<BR />
Methods: Patients aged ≥18 years with mild-severe psoriasis were enrolled into three Phase II/III studies (nCT01536886, nCT01536938, nCT01866163); each study evaluated Cal/BD aerosol foam versus different comparators. Endpoints included: proportion of patients clear/almost clear with ≥2-step improvement in physician's global assessment of disease severity ('treatment success'); modified (excluding head) psoriasis area and severity index (mPASI); proportion of patients with ≥75% reduction in mPASI (PASI75); change in itch (according to visual analog scale [VAS]).<BR />
Results: 1104 patients were included in the pooled analysis: Cal/BD aerosol foam (n=564), Cal/BD ointment (n=135), BD aerosol foam (n=101), Cal aerosol foam (n=101), aerosol foam vehicle (n=152), ointment vehicle (n=51). At week 4, 51% of Cal/BD aerosol foam patients achieved treatment success, a higher proportion than in all other groups (Cal/BD ointment, 43%; BD aerosol foam, 31%; Cal aerosol foam, 15%; aerosol foam vehicle, 5%; ointment vehicle, 8%). Greater percentage mean decrease in mPASI with Cal/BD aerosol foam was noted versus other treatments at week 4 (72% vs 63%, 53%, 43%, 32%, and 33%, respectively); week 4 PASI75 rate was also greater (51% vs 41%, 34%, 18%, 7%, and 10%, respectively). Cal/BD aerosol foam was efficacious irrespective of baseline disease severity and on all body areas assessed (arms, legs, trunk). Cal/BD aerosol foam alleviated itch as early as week 1 (change in itch VAS: -30 mm), maintained to week 4 (change in itch VAS: -41 mm).<BR />
Conclusions: Cal/BD aerosol foam was significantly more effective than Cal/BD ointment and the individual active ingredients for treating psoriasis vulgaris, resulting in greater and faster reduction in disease severity and rapid, effective relief of itch.<BR /><BR /> <em>J Drugs Dermatol</em>. 2016;15(8):951-957.
Similar articles
-
Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).J Drugs Dermatol. 2015 Dec;14(12):1468-77. J Drugs Dermatol. 2015. PMID: 26659941 Clinical Trial.
-
Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.J Dermatolog Treat. 2016;27(2):120-7. doi: 10.3109/09546634.2015.1083935. Epub 2015 Oct 7. J Dermatolog Treat. 2016. PMID: 26444907 Free PMC article. Clinical Trial.
-
The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study.J Drugs Dermatol. 2016 Aug 1;15(8):981-7. J Drugs Dermatol. 2016. PMID: 27537999 Clinical Trial.
-
Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies.Skinmed. 2017 Apr 1;15(2):119-124. eCollection 2017. Skinmed. 2017. PMID: 28528605 Review.
-
Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile.Expert Opin Pharmacother. 2017 Jan;18(1):115-121. doi: 10.1080/14656566.2016.1269749. Expert Opin Pharmacother. 2017. PMID: 27936972 Review.
Cited by
-
Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis.Dermatol Ther (Heidelb). 2020 Dec;10(6):1383-1396. doi: 10.1007/s13555-020-00454-z. Epub 2020 Oct 13. Dermatol Ther (Heidelb). 2020. PMID: 33048333 Free PMC article.
-
Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use.Dermatol Pract Concept. 2021 May 20;11(3):e2021056. doi: 10.5826/dpc.1103a56. eCollection 2021 May. Dermatol Pract Concept. 2021. PMID: 34123560 Free PMC article.
-
Treatment of Psoriasis: Novel Approaches to Topical Delivery.Open Access Maced J Med Sci. 2019 Aug 30;7(18):3018-3025. doi: 10.3889/oamjms.2019.414. eCollection 2019 Sep 30. Open Access Maced J Med Sci. 2019. PMID: 31850114 Free PMC article. Review.
-
Efficacy of Fixed-combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam for Scalp Plaque Psoriasis: Additional Analysis of a Phase II, Randomized Clinical Study.J Clin Aesthet Dermatol. 2020 May;13(5):12-18. Epub 2020 May 1. J Clin Aesthet Dermatol. 2020. PMID: 32802249 Free PMC article.
-
Associations Between Factors Affecting Itching and Quality of Life in Thai Patients with Psoriasis: A Cross-Sectional Study.F1000Res. 2025 Apr 25;13:1242. doi: 10.12688/f1000research.156703.2. eCollection 2024. F1000Res. 2025. PMID: 40416300 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials